HF
OCUL icon

HRT Financial’s Ocular Therapeutix OCUL Stock Holding History

HRT Financial’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-62,500
Closed -$758K – 4451
2025
Q4 		$758K Buy
+62,500
New +$759K ﹤0.01% 1875

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

HRT Financial's OCUL Position: Q2 2026 in Review

HRT Financial increased its Ocular Therapeutix (OCUL) stake by 52% in Q2 2026, buying an estimated $3.33M and bringing the position to 1,077,090 shares worth $10.6M. The position accounts for 0.02% of the portfolio, ranked #756.

HRT Financial first reported a position in OCUL in Q4 2019 and has held it in 11 quarters since. 262 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • HRT Financial held 1,077,090 shares of Ocular Therapeutix worth $10.6M as of Q2 2026.
  • HRT Financial bought 367,872 Ocular Therapeutix shares in Q2 2026, an estimated $3.33M.
  • Ocular Therapeutix made up 0.02% of HRT Financial's portfolio in Q2 2026, its #756 holding.
  • HRT Financial first reported a position in Ocular Therapeutix in Q4 2019 and has held it in 11 quarters since.
  • 262 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.